相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Risperidone Exacerbates Glucose Intolerance, Nonalcoholic Fatty Liver Disease, and Renal Impairment in Obese Mice
Hsiao-Pei Tsai et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment
Muyue Yang et al.
BIOACTIVE MATERIALS (2021)
Cancers in Taiwan: Practical insight from epidemiology, treatments, biomarkers, and cost
Chun-Nan Kuo et al.
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION (2020)
The role of NF-κB and AhR transcription factors in lead-induced lung toxicity in human lung cancer A549 cells
Ibraheem M. Attafi et al.
TOXICOLOGY MECHANISMS AND METHODS (2020)
Activation of notch 3/c-MYC/CHOP axis regulates apoptosis and promotes sensitivity of lung cancer cells to mTOR inhibitor everolimus
Ting Li et al.
BIOCHEMICAL PHARMACOLOGY (2020)
mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
Zhilin Zou et al.
CELL AND BIOSCIENCE (2020)
The In Vitro and In Vivo Anticancer Properties of Chalcone Flavokawain B through Induction of ROS-Mediated Apoptotic and Autophagic Cell Death in Human Melanoma Cells
You-Cheng Hseu et al.
CANCERS (2020)
Mirtazapine Reduces Adipocyte Hypertrophy and Increases Glucose Transporter Expression in Obese Mice
Ching-Feng Wu et al.
ANIMALS (2020)
Papain bioinspired gold nanoparticles augmented the anticancer potency of 5-FU against lung cancer
Tong Li et al.
JOURNAL OF EXPERIMENTAL NANOSCIENCE (2020)
Antrodia camphorata inhibits epithelial-to-mesenchymal transition by targeting multiple pathways in triple-negative breast cancers
You-Cheng Hseu et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
mTOR inhibitor Everolimus-induced apoptosis in melanoma cells
Dorota Ciolczyk-Wierzbicka et al.
JOURNAL OF CELL COMMUNICATION AND SIGNALING (2019)
Everolimus inhibits the proliferation and migration of epidermal growth factor receptor-resistant lung cancer cells A549 via regulating the microRNA-4328/phosphatase and tensin homolog signaling pathway
Xudong Xiang et al.
ONCOLOGY LETTERS (2019)
ZEB1-AS1 is associated with poor prognosis in non-small-cell lung cancer and influences cell migration and apoptosis by repressing ID1
Jianjun Jin et al.
CLINICAL SCIENCE (2019)
Mechanisms of Phytonutrient Modulation of Cyclooxygenase-2 (COX-2) and Inflammation Related to Cancer
Shreena J. Desai et al.
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL (2018)
Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression
Anzhou Xia et al.
ONCOLOGY REPORTS (2018)
The A(2B) Adenosine Receptor Modulates the Epithelial-Mesenchymal Transition through the Balance of cAMP/PKA and MAPK/ERK Pathway Activation in Human Epithelial Lung Cells
Chiara Giacomelli et al.
FRONTIERS IN PHARMACOLOGY (2018)
The combination of curcumin and 5-fluorouracil in cancer therapy
Yumeng Wei et al.
ARCHIVES OF PHARMACAL RESEARCH (2018)
Correlation analysis between expression of PCNA, Ki-67 and COX-2 and X-ray features in mammography in breast cancer
Xiaoming Qiu et al.
ONCOLOGY LETTERS (2017)
CD44 Interacts with HIF-2α to Modulate the Hypoxic Phenotype of Perinecrotic and Perivascular Glioma Cells
Elinn Johansson et al.
CELL REPORTS (2017)
Celecoxib normalizes the tumor microenvironment and enhances small nanotherapeutics delivery to A549 tumors in nude mice
Bo Zhang et al.
SCIENTIFIC REPORTS (2017)
NF-kappa B signaling in inflammation
Ting Liu et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2017)
Towards natural mimetics of metformin and rapamycin
Alexander Aliper et al.
AGING-US (2017)
A review on the effects of current chemotherapy drugs and natural agents in treating non-small cell lung cancer
Chih-Yang Huang et al.
BIOMEDICINE-TAIWAN (2017)
mTOR Signaling in Growth, Metabolism, and Disease
Robert A. Saxton et al.
CELL (2017)
Survivin activates NF-κB p65 via the IKKβ promoter in esophageal squamous cell carcinoma
Wei Zeng et al.
MOLECULAR MEDICINE REPORTS (2016)
Synergistic effects of CD44 and TGF-β1 through AKT/GSK-3β/β-catenin signaling during epithelial-mesenchymal transition in liver cancer cells
Na Ri Park et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2016)
Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma
Sarah A. Weiss et al.
HUMAN PATHOLOGY (2016)
Synergistic anticancer effects of andrographolide and paclitaxel against A549 NSCLC cells
Huihui Yuan et al.
PHARMACEUTICAL BIOLOGY (2016)
A genetic cell context-dependent role for ZEB1 in lung cancer
Ting Zhang et al.
NATURE COMMUNICATIONS (2016)
The mTOR inhibitor Everolimus synergizes with the PI3K inhibitor GDC0941 to enhance anti-tumor efficacy in uveal melanoma
Nabil Amirouchene-Angelozzi et al.
ONCOTARGET (2016)
Rapamycin impairs HPD-induced beneficial effects on glucose homeostasis
Geng-Ruei Chang et al.
BRITISH JOURNAL OF PHARMACOLOGY (2015)
Prognostic Role of Tumor-Infiltrating Lymphocytes in Lung Cancer: a Meta-Analysis
Yiting Geng et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2015)
Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin
Matthew G. Oser et al.
LANCET ONCOLOGY (2015)
Cancers Complicating Inflammatory Bowel Disease
Laurent Beaugerie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Cancer metastases: challenges and opportunities
Xiangming Guan
ACTA PHARMACEUTICA SINICA B (2015)
Role of LKB1-CRTC1 on Glycosylated COX-2 and Response to COX-2 Inhibition in Lung Cancer
Chunxia Cao et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Ki67 is a promising molecular target in the diagnosis of cancer
Lian Tao Li et al.
MOLECULAR MEDICINE REPORTS (2015)
The structural network of Interleukin-10 and its implications in inflammation and cancer
Ece Saliha Acuner-Ozbabacan et al.
BMC GENOMICS (2014)
The role of PI3K/AKT/mTOR pathway in the modulation of autophagy and the clearance of protein aggregates in neurodegeneration
David Heras-Sandoval et al.
CELLULAR SIGNALLING (2014)
Cisplatin in cancer therapy: Molecular mechanisms of action
Shaloam Dasari et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2014)
Everolimus prolonged survival in transgenic mice with EGFR-driven lung tumors
Masayuki Yasugi et al.
EXPERIMENTAL CELL RESEARCH (2014)
Overcoming 5-Fu resistance in human non-small cell lung cancer cells by the combination of 5-Fu and cisplatin through the inhibition of glucose metabolism
Jun-gang Zhao et al.
TUMOR BIOLOGY (2014)
Systems biology of cisplatin resistance: past, present and future
L. Galluzzi et al.
CELL DEATH & DISEASE (2014)
Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention
Nicole M. Davis et al.
ONCOTARGET (2014)
Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice
Dipti K. Pawaskar et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Ellagic acid inhibits human pancreatic cancer growth in Balb c nude mice
Min Zhao et al.
CANCER LETTERS (2013)
Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: A systematic review of incidence, manifestations and predisposing factors
Anne Polk et al.
CANCER TREATMENT REVIEWS (2013)
mTOR in aging, metabolism, and cancer
Marion Cornu et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2013)
Zotarolimus- Versus Everolimus-Eluting Stents for Unprotected Left Main Coronary Artery Disease
Julinda Mehilli et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
NF-κB and the link between inflammation and cancer
Joseph A. DiDonato et al.
IMMUNOLOGICAL REVIEWS (2012)
The translational landscape of mTOR signalling steers cancer initiation and metastasis
Andrew C. Hsieh et al.
NATURE (2012)
Inhibition of mTOR by temsirolimus contributes to prolonged survival of mice with pleural dissemination of non-small-cell lung cancer cells
Toshiaki Ohara et al.
CANCER SCIENCE (2011)
Effects of mTOR Inhibitor Everolimus (RAD001) on Bladder Cancer Cells
Edmund Chiong et al.
CLINICAL CANCER RESEARCH (2011)
Apoptosis in cancer: from pathogenesis to treatment
Rebecca S. Y. Wong
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2011)
Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens
Victor M. Rivera et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Non-small-cell lung cancer
Peter Goldstraw et al.
LANCET (2011)
mTOR: from growth signal integration to cancer, diabetes and ageing
Roberto Zoncu et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2011)
Pharmacokinetic properties and antitumor efficacy of the 5-fluorouracil loaded PEG-hydrogel
Hee Yi et al.
BMC CANCER (2010)
Autocrine VEGF Signaling Synergizes with EGFR in Tumor Cells to Promote Epithelial Cancer Development
Beate M. Lichtenberger et al.
CELL (2010)
Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids
Maria Chiara Zatelli et al.
ENDOCRINE-RELATED CANCER (2010)
Long-term Administration of Rapamycin Reduces Adiposity, but Impairs Glucose Tolerance in High-Fat Diet-fed KK/HlJ Mice
Geng-Ruei Chang et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2009)
Rapamycin Protects Against High Fat Diet-Induced Obesity in C57BL/6J Mice
Geng-Ruei Chang et al.
JOURNAL OF PHARMACOLOGICAL SCIENCES (2009)
Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy
Andrea Koch et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs
R. Bianco et al.
BRITISH JOURNAL OF CANCER (2008)
Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo
Daniel Cejka et al.
CANCER BIOLOGY & THERAPY (2008)
Cancer-related inflammation
Alberto Mantovani et al.
NATURE (2008)
IKKβ suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway
Dung-Fang Lee et al.
CELL (2007)
Possible involvement of persistent activity of the mammalian target of rapamycin pathway in the cisplatin resistance of AFP-producing gastric cancer cells
Shigeyuki Kamata et al.
CANCER BIOLOGY & THERAPY (2007)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Gary Hudes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
RAD001 (everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer
Seiji Mabuchi et al.
CANCER RESEARCH (2007)
5-Fluorouracil dose escalation enabled with PN401 (triacetyluridine): toxicity reduction and increased antitumor activity in mice
MW Saif et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2006)
EGF-ERBB signalling: towards the systems level
Ami Citri et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2006)
Zotarolimus (ABT-578) eluting stents
Sandra E. Burke et al.
ADVANCED DRUG DELIVERY REVIEWS (2006)
Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members
Michael Certo et al.
CANCER CELL (2006)
NFκB:: Linking inflammation and immunity to cancer development and progression
M Karin et al.
NATURE REVIEWS IMMUNOLOGY (2005)
Critical update and emerging trends in epidermal growth factor receptor targeting in cancer
J Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
ABT-578-eluting stents - The promising successor of sirolimus- and paclitaxel-eluting stent concepts?
L Buellesfeld et al.
HERZ (2004)
NF-κB functions as a tumour promoter in inflammation-associated cancer
E Pikarsky et al.
NATURE (2004)
Cisplatin: mode of cytotoxic action and molecular basis of resistance
ZH Siddik
ONCOGENE (2003)
Tumor necrosis factor-α-induced IKK phosphorylation of NF-κB p65 on serine 536 is mediated through the TRAF2, TRAF5, and TAK1 signaling pathway
H Sakurai et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Growth factors and chemotherapeutic modulation of breast cancer cells
K Ciftci et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2003)
IL-10-inducible Bcl-3 negatively regulates LPS-induced TNF-alpha production in macrophages
H Kuwata et al.
BLOOD (2003)
A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.
M Morice et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor
M Guba et al.
NATURE MEDICINE (2002)
p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD
H Harada et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
TGFβ signaling in growth control, cancer, and heritable disorders
J Massagué et al.
CELL (2000)
分享论文
